MedTrace Logo

Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC

NCT04375150 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 355

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

The study aims to assess treatment patterns and outcomes in advanced RCC patients in real world clinical practices across various real world databases. Four databases will be evaluated

Conditions

  • Renal Cell Carcinoma (RCC)

Interventions

DRUG

Tyrosine kinase inhibitor (TKI)

TKIs

DRUG

Immuno-oncology (IO)

IOs

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-02
Primary Completion
2022-10-28
Completion
2022-10-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04375150 on ClinicalTrials.gov